Antiproliferative Activity of Egg Yolk Peptides in Human Colon Cancer Cells.
Egg yolk peptides were successfully prepared from egg yolk protein by-products after lecithin extraction. Defatted egg yolk protein was hydrolyzed with pepsin and pancreatin and purified by gel filtration to produce egg yolk gel filtration fraction (EYGF-33) with antiproliferative activity. The highlight of this study was that the peptide EYGF-33 (1.0 mg/ml) significantly inhibits cell viability of colon cancer cells (Caco-2) with no inhibitory effects on the viability of human colon epithelial normal cells (HCEC) after 48 h. Reduced cell viability can be explained by cell cycle arrest in the S-phase in which DNA replication normally takes place. EYGF-33 significantly enhanced the production of superoxide anions in the mitochondria of Caco-2 cells; this could activate a mitochondrial apoptotic pathway leading to typical Poly Adenosine diphosphate-ribose polymerase (PARP) cleavage as observed in the Western blot result. The induction of apoptotic cell death by EYGF-33 was supported by the externalization of phosphatidylserine (PS). However, further elucidation of the mechanism of EYGF-33-mediated apoptosis would provide further support for its use as a potential therapeutic and chemopreventive agent.
a Faculty of Health and Medical Sciences, School of Biosciences and Medicine , University of Surrey , Guildford, Surrey , UK.
Marwa N
MN
Yousr
b Faculty of Sciences and Arts-Alkamel, Department of Biology , University of Jeddah , Jeddah , Saudi Arabia.
Akram A
AA
Aloqbi
c Faculty of Science, Department of Biochemistry , University of King Abdulaziz , Jeddah , Saudi Arabia.
Ulfat M
UM
Omar
a Faculty of Health and Medical Sciences, School of Biosciences and Medicine , University of Surrey , Guildford, Surrey , UK.
Nazlin K
NK
Howell
D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D018938:Caco-2 Cells / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms / Q000473:pathology / Q000517:prevention & control; D004527:Egg Proteins / Q000494:pharmacology*; D006801:Humans; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology; D010718:Phosphatidylserines / Q000378:metabolism; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D013481:Superoxides / Q000378:metabolism
D016588:Anticarcinogenic Agents; C000620901:EYGF-33 peptide, human; D004527:Egg Proteins; D010455:Peptides; D010718:Phosphatidylserines; D017382:Reactive Oxygen Species; D013481:Superoxides; D011065:Poly(ADP-ribose) Polymerases